Sanofi Oncology

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Nura Bio, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing neuroprotective therapies aimed at treating neurological diseases. The company specializes in discovering and developing drugs that prevent axon loss following acute injury or chronic degenerative conditions. Its primary drug candidate, NB-4746, is designed to inhibit the SARM1 protein, which is implicated in axonal degeneration. This candidate has shown promise in preclinical studies for preventing nerve damage and is progressing toward phase 1b/2 clinical trials scheduled for 2025. Nura Bio has successfully raised $140 million in financing to support its drug development initiatives and enhance the immune response of the nervous system following neurological injuries.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutic antibodies for inflammation and immuno-oncology. The company’s key product candidates include Etokimab, an anti-IL-33 treatment for atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis; and several immune cell modulating antibodies, including checkpoint agonists for autoimmune diseases. AnaptysBio's pipeline features notable immuno-oncology candidates such as TSR-042 (anti-PD-1), TSR-022 (anti-TIM-3), and TSR-075 (anti-PD-1/LAG-3 bispecific). The company employs a proprietary platform based on somatic hypermutation for antibody discovery and optimization, addressing unmet medical needs in therapeutic applications. AnaptysBio has formed partnerships with various organizations, including TESARO and Celgene, to enhance its research and development efforts. Founded in 2005, AnaptysBio has established itself in the biotechnology sector as a developer of innovative therapies targeting significant health challenges.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

We are a pharmaceutical company dedicated to improving access to medicine in East & Central Africa. We mainly focus on data-driven healthcare solutions that increase access and quality of information as well as facilitate safe, effective, and sustainable pharmaceutical supply chains across the industry. Our mission is to increase access to high-quality medicines, services, and information via technology solutions that improve affordability, health outcomes, and ease of use.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Medisafe is a digital patient engagement platform focused on improving medication adherence and management. By utilizing a data-driven approach, the platform personalizes patient engagement, helping users navigate the complexities of their medication schedules. Medisafe addresses common challenges associated with non-adherence by providing features that send alerts to users and their caretakers, ensuring timely medication intake. With nearly 5 million registered users and over 2 billion recorded medication doses, the app has demonstrated its effectiveness in improving adherence by up to 20%, as evidenced by various studies. The platform engages both patients and healthcare partners, offering insights into behavior patterns that enhance the patient experience. Medisafe has received multiple accolades for its innovation in healthcare, including recognition from Gartner and Fast Company, and boasts high user satisfaction ratings, making it a leading solution in medication management.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

i2O Therapeutics, established in 2019 and headquartered in Saratoga, California, specializes in converting injectable biologic therapies into orally administrable pills using its proprietary ionic liquid technology. This innovative approach aims to enhance the permeability of epithelial barriers, enabling safe and effective oral delivery of peptides, proteins, and other traditionally injected drugs. The company focuses on developing next-generation oral therapies for metabolic and inflammatory diseases.

Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, focused on developing innovative cytokine Synthorin programs for the treatment of cancer and autoimmune disorders. The company's lead product candidate, THOR-707, is a variant of recombinant human IL-2 being explored for various solid tumors, both as a standalone treatment and in combination with immune checkpoint inhibitors. Additionally, Synthorx is working on IL-2 Synthorin for autoimmune conditions, IL-10 Synthorin for immuno-oncology, and IL-15 Synthorins to enhance immune regulation. The company employs advanced synthetic biology techniques, utilizing a novel DNA base pair to create proteins with enhanced specificity, safety, and efficacy. These developments enable the manufacturing of improved therapeutics that can better modulate pharmacological properties compared to traditional biologics. Synthorx, which was established in 2014 and previously known as Alinos, Inc., operates as a subsidiary of Sanofi and holds exclusive rights to its innovative synthetic biology technology derived from research at The Scripps Research Institute.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

Imbria Pharmaceuticals, Inc. is a clinical-stage pharmaceuticals company based in Boston, Massachusetts, founded in 2018. The company specializes in developing innovative therapies aimed at addressing cardiometabolic disorders by enhancing or restoring cellular energy production. Imbria's research focuses on the mechanisms underlying these conditions, particularly in areas such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. By translating scientific insights into practical treatments, Imbria Pharmaceuticals aims to meet significant unmet medical needs and improve the lives of patients affected by these life-altering disorders. Through its commitment to understanding cellular metabolism and mitochondrial function, the company works to advance healthcare solutions in the cardiometabolic space.

Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These innovative proteins are designed to address a variety of serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. Currently, Ablynx has around 25 projects in its pipeline, with five Nanobodies in clinical development. By combining the advantages of traditional antibodies and small chemical molecules, Ablynx aims to provide new therapeutic options that can significantly improve patient care and outcomes.

Bioverativ Inc. is a biopharmaceutical company focused on developing therapies for hemophilia and other rare blood disorders, including cold agglutinin disease, sickle cell disease, and beta thalassemia. Founded in 2016 and headquartered in Waltham, Massachusetts, the company aims to transform the lives of patients through innovative research and development. Bioverativ's pipeline features hemophilia therapies that offer less-frequent prophylactic dosing for hemophilia A and subcutaneous dosing for hemophilia B, as well as gene therapy programs for both types of hemophilia. Additionally, the company is working on Sutimlimab, a treatment aimed at inhibiting the complement pathway of the immune system to address cold agglutinin disease. As a subsidiary of Sanofi, Bioverativ continues to advance its mission to provide effective treatments for chronic blood disorders.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Thermalin, Inc. is a biotechnology company based in Cleveland, Ohio, founded in 2010, that specializes in developing innovative insulin therapies for individuals with Type 1 and Type 2 diabetes. The company aims to disrupt the insulin and insulin delivery market with its first-in-class, ultra-rapid acting insulin, which is stabilized and highly concentrated. This new insulin formulation is designed for use in a disposable, postage-stamp-sized glucose management system and can also be utilized in existing insulin pumps. In addition to its lead program, Thermalin is exploring partnerships to develop no-cold-chain basal and mix insulins, as well as glucose-responsive insulins. By creating insulin analogs that do not require refrigeration and are rapidly absorbed, Thermalin seeks to reduce the burden of insulin therapy, thereby improving patient adherence and health outcomes.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs associated with X-linked adrenoleukodystrophy (X-ALD). Neurovia's primary objective is to provide a treatment that can halt the progression of neurological deficits caused by this rare genetic disease. The company has developed a selective thyromimetic agent aimed at improving the quality of life for patients suffering from X-ALD.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

ImmuneXcite is a biopharmaceutical company based in Lexington, Massachusetts, founded in 2007. The company specializes in developing monoclonal antibodies for cancer treatment, utilizing its proprietary mAbXcite platform technology. This innovative approach enhances the efficacy of therapeutic monoclonal antibodies by chemically linking a unique carbohydrate that activates neutrophils, thereby targeting cancer cells for destruction. The research underpinning ImmuneXcite's technology originated from the Whitehead Institute at MIT and has received support from various institutions, including the Massachusetts Technology Transfer Center and the National Cancer Institute. By leveraging both innate and adaptive immune responses, ImmuneXcite aims to create next-generation immune-activating biotherapeutics that selectively treat a wide range of tumor types, ultimately helping to limit tumor growth and metastasis.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, focused on developing innovative therapies for patients with neurological disorders, particularly rare diseases. Founded in 2014, the company is advancing a promising pipeline of drug candidates aimed at treating conditions such as angelman syndrome and fragile X syndrome. Its lead candidate, OV101, is in Phase III clinical trials for angelman syndrome and has completed Phase II trials for fragile X syndrome. Additionally, Ovid is developing OV935, currently in Phase II trials for cyclin-dependent kinase-like 5 deficiency disorder and Dravet syndrome. The company is also researching OV329 for infantile spasms and OV881 as a microRNA gene therapy for angelman syndrome. Ovid Therapeutics has established collaborations and licensing agreements with various pharmaceutical and research organizations to enhance its development efforts. The company's commitment to addressing unmet medical needs is underpinned by strong intellectual property and a focus on safe, effective treatments for patients facing challenging neurological conditions.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Portal Instruments, Inc. is a clinical-stage medical device company based in Cambridge, Massachusetts, specializing in needle-free drug delivery systems. Founded in 2012, the company designs and manufactures jet injectors that administer medications through the skin using a narrow stream, allowing for precise delivery at specific depths and volumes. This innovative technology aims to enhance the patient experience by providing a painless, silent, and safe alternative to traditional needles and syringes. Portal Instruments' platform is compatible with a wide range of pharmaceutical manufacturing processes and is designed to accommodate various medical, animal, agricultural, and cosmetic applications. The company's goal is to become the standard for modern drug delivery, transforming how medications are administered to patients with chronic diseases.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing genomic technology to discover drugs of natural origin. Founded in 2010, the company utilizes a proprietary genomic search engine and customized search queries to uncover hidden natural products by analyzing their unique genomic signatures. This innovative approach allows researchers to generate novel drug candidates and understand their mechanisms of action, facilitating the conversion of genomic data into potential therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.

Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Nepentes Pharma Sp. z o.o. is a pharmaceutical company focused on the manufacturing and distribution of various healthcare products, including Iwostin, Emolium, Elixine, Propodia, ApiPanten, Propolki, and Propolets. The company is dedicated to enhancing brand presence in pharmacies by coordinating the development, implementation, and oversight of effective marketing strategies. Operating primarily in Central and Eastern Europe, Nepentes Pharma aims to provide high-quality products while ensuring optimal market performance through comprehensive business activities.

BMP Sunstone Corporation is a specialty pharmaceutical company focused on developing a proprietary portfolio of branded pharmaceutical and healthcare products in China. The company manufactures and sells a range of pediatric and women's health products through pharmacies nationwide. In addition to its own products, BMP Sunstone markets items under exclusive multi-year licenses, primarily targeting women's health and pediatric care. The company also offers pharmaceutical distribution services via its subsidiaries located in Beijing and Shanghai.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in the discovery and development of small molecule kinase inhibitors targeting vascular leakage, angiogenesis, and inflammation. Founded in 2002, TargeGen focuses on creating treatments for various serious medical conditions, including heart attacks, cancer, and eye diseases. The company's products address issues such as vascular leakage, edema, the abnormal growth of new blood vessels, and conditions like pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and hypovolemia. TargeGen also serves specific markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. The company was acquired in 2010, which has further enhanced its capabilities in addressing critical health challenges.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

Medley, the third-largest pharmaceutical firm in Brazil, and the number one generic drugs group in the country.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.